Arrowstreet Capital Limited Partnership Has $669.01 Million Stock Position in Bristol Myers Squibb Company $BMY

Arrowstreet Capital Limited Partnership increased its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY) by 31.1% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 14,833,977 shares of the biopharmaceutical company’s stock after acquiring an additional 3,522,696 shares during the period. Arrowstreet Capital Limited Partnership owned about 0.73% of Bristol Myers Squibb worth $669,012,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Darwin Wealth Management LLC acquired a new position in Bristol Myers Squibb during the 2nd quarter worth about $25,000. Harbor Capital Advisors Inc. boosted its holdings in Bristol Myers Squibb by 107.2% during the third quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 313 shares during the last quarter. Total Investment Management Inc. bought a new stake in shares of Bristol Myers Squibb in the 2nd quarter valued at $38,000. Twin Peaks Wealth Advisors LLC acquired a new position in shares of Bristol Myers Squibb in the 2nd quarter valued at approximately $40,000. Finally, Bank of Jackson Hole Trust boosted its stake in Bristol Myers Squibb by 352.2% in the 3rd quarter. Bank of Jackson Hole Trust now owns 1,040 shares of the biopharmaceutical company’s stock worth $47,000 after purchasing an additional 810 shares during the period. 76.41% of the stock is owned by institutional investors.

Bristol Myers Squibb Stock Performance

Shares of Bristol Myers Squibb stock opened at $58.93 on Friday. Bristol Myers Squibb Company has a 1-year low of $42.52 and a 1-year high of $62.89. The company has a current ratio of 1.26, a quick ratio of 1.14 and a debt-to-equity ratio of 2.32. The business has a 50-day moving average price of $58.12 and a two-hundred day moving average price of $51.32. The company has a market cap of $120.00 billion, a P/E ratio of 17.08, a PEG ratio of 0.17 and a beta of 0.26.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, February 5th. The biopharmaceutical company reported $1.26 EPS for the quarter, missing the consensus estimate of $1.65 by ($0.39). Bristol Myers Squibb had a return on equity of 69.65% and a net margin of 14.64%.The company had revenue of $12.50 billion for the quarter, compared to analyst estimates of $12.24 billion. During the same period last year, the business earned $1.67 EPS. The business’s quarterly revenue was up 1.3% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, analysts anticipate that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 1st. Shareholders of record on Thursday, April 2nd will be paid a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 4.3%. The ex-dividend date of this dividend is Thursday, April 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is 73.04%.

Analyst Ratings Changes

A number of analysts have recently commented on BMY shares. Wells Fargo & Company reissued an “outperform” rating and issued a $60.00 price objective (up from $55.00) on shares of Bristol Myers Squibb in a research report on Friday, February 6th. UBS Group reaffirmed a “buy” rating and set a $70.00 target price on shares of Bristol Myers Squibb in a report on Friday, March 6th. Citigroup increased their price objective on Bristol Myers Squibb from $60.00 to $64.00 and gave the stock a “neutral” rating in a research report on Friday, February 6th. HSBC reiterated a “hold” rating and issued a $53.00 price target on shares of Bristol Myers Squibb in a research note on Wednesday, December 10th. Finally, Bank of America raised shares of Bristol Myers Squibb from a “neutral” rating to a “buy” rating and raised their target price for the company from $52.00 to $61.00 in a report on Monday, December 15th. Nine investment analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $61.00.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.